Characterization of dextran sodium sulfate-induced inflammation and colonic tumorigenesis in Smad3-/- mice with dysregulated TGFβ

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Seamons, Audrey ^a   Treuting, Piper M ^a   Brabb, Thea ^a   Maggio Price, Lillian ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL MARKER; DEXTRAN SULFATE; GALECTIN 3; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ACUTE TYPHLOCOLITIS; ADENOMATOUS POLYP; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOODY DIARRHEA; CELL PROLIFERATION; COLITIS; COLON CARCINOGENESIS; COLORECTAL TUMOR; CONTROLLED STUDY; DEHYDRATION; DIGESTIVE SYSTEM INJURY; DISEASE PREDISPOSITION; DISEASE SEVERITY; DYSPLASIA; EXPERIMENTAL INFLAMMATORY BOWEL DISEASE; HERNIA; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MOUSE; MUCINOUS NEOPLASIA; NONHUMAN; SQUAMOUS CELL METAPLASIA; SURVIVAL; TRANSGENIC MOUSE; TUMOR VOLUME; WEIGHT REDUCTION; WILD TYPE;

ANIMALS; COLITIS; COLORECTAL NEOPLASMS; DEXTRAN SULFATE; DNA-BINDING PROTEINS; HUMANS; INFLAMMATION; MICE; MICE, KNOCKOUT; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

EID: 84892980000     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0079182     Document Type: Article

References (55)

1. Bernstein CN, Blanchard JF, Kliewer E, Wajda A (2001) Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer 91: 854-862. (Pubitemid 32173312)
2. Westbrook AM, Szakmary A, Schiestl RH (2010) Mechanisms of intestinal inflammation and development of associated cancers: lessons learned from mouse models. Mutation research 705: 40-59.
3. Mladenova D, Kohonen-Corish MR (2012) Review: Mouse models of inflammatory bowel disease-insights into the mechanisms of inflammation- associated colorectal cancer. In vivo 26: 627-646.
4. Kanneganti M, Mino-Kenudson M, Mizoguchi E (2011) Animal models of colitis-associated carcinogenesis. Journal of biomedicine & biotechnology 2011: 342637.
5. Washington MK, Powell AE, Sullivan R, Sundberg JP, Wright N, et al. (2013) Pathology of rodent models of intestinal cancer: progress report and recommendations. Gastroenterology 144: 705-717.
6. Boivin GP, Washington K, Yang K, Ward JM, Pretlow TP, et al. (2003) Pathology of mouse models of intestinal cancer: consensus report and recommendations. Gastroenterology 124: 762-777. (Pubitemid 36268493)
7. Bierie B, Moses HL (2010) Transforming growth factor beta (TGF-beta) and inflammation in cancer. Cytokine & growth factor reviews 21: 49-59.
8. Lampropoulos P, Zizi-Sermpetzoglou A, Rizos S, Kostakis A, Nikiteas N, et al. (2012) TGF-beta signalling in colon carcinogenesis. Cancer letters 314: 1-7.
9. Xavier RJ, Podolsky DK (2007) Unravelling the pathogenesis of inflammatory bowel disease. Nature 448: 427-434. (Pubitemid 47123518)
10. Maloy KJ, Powrie F (2011) Intestinal homeostasis and its breakdown in inflammatory bowel disease. Nature 474: 298-306.
11. Xu L (2006) Regulation of Smad activities. Biochimica et biophysica acta 1759: 503-513.
12. Munoz NM, Upton M, Rojas A, Washington MK, Lin L, et al. (2006) Transforming growth factor beta receptor type II inactivation induces the malignant transformation of intestinal neoplasms initiated by Apc mutation. Cancer research 66: 9837-9844. (Pubitemid 44672034)
13. Biswas S, Chytil A, Washington K, Romero-Gallo J, Gorska AE, et al. (2004) Transforming growth factor beta receptor type II inactivation promotes the establishment and progression of colon cancer. Cancer research 64: 4687-4692. (Pubitemid 38924506)
14. Takaku K, Oshima M, Miyoshi H, Matsui M, Seldin MF, et al. (1998) Intestinal tumorigenesis in compound mutant mice of both Dpc4 (Smad4) and Apc genes. Cell 92: 645-656. (Pubitemid 28141513)
15. Zhu Y, Richardson JA, Parada LF, Graff JM (1998) Smad3 mutant mice develop metastatic colorectal cancer. Cell 94: 703-714. (Pubitemid 28436003)
16. Maggio-Price L, Treuting P, Zeng W, Tsang M, Bielefeldt-Ohmann H, et al. (2006) Helicobacter infection is required for inflammation and colon cancer in SMAD3-deficient mice. Cancer Res 66: 828-838. (Pubitemid 43165948)
17. Maggio-Price L, Treuting P, Bielefeldt-Ohmann H, Seamons A, Drivdahl R, et al. (2009) Bacterial infection of Smad3/Rag2 double-null mice with transforming growth factor-beta dysregulation as a model for studying inflammation-associated colon cancer. Am J Pathol 174: 317-329.
18. Deane NG, Manning HC, Foutch AC, Washington MK, Aronow BJ, et al. (2007) Targeted imaging of colonic tumors in smad3-/- mice discriminates cancer and inflammation. Molecular cancer research : MCR 5: 341-349. (Pubitemid 46706996)
19. Perse M, Cerar A (2012) Dextran sodium sulphate colitis mouse model: traps and tricks. Journal of biomedicine & biotechnology 2012: 718617.
20. Lencioni KC, Drivdahl R, Seamons A, Treuting PM, Brabb T, et al. (2011) Lack of effect of murine norovirus infection on a mouse model of bacteria-induced colon cancer. Comparative medicine 61: 219-226.
21. Burich A, Hershberg R, Waggie K, Zeng W, Brabb T, et al. (2001) Helicobacter-induced inflammatory bowel disease in IL-10- and T cell-deficient mice. Am J Physiol Gastrointest Liver Physiol 281: G764-778.
22. Moolenbeek C, Ruitenberg EJ (1981) The "Swiss roll": a simple technique for histological studies of the rodent intestine. Laboratory animals 15: 57-59. (Pubitemid 11185576)
23. Fort MM, Mozaffarian A, Stover AG, Correia Jda S, Johnson DA, et al. (2005) A synthetic TLR4 antagonist has anti-inflammatory effects in two murine models of inflammatory bowel disease. Journal of immunology 174: 6416-6423. (Pubitemid 40663835)
24. Mahler M, Bristol IJ, Leiter EH, Workman AE, Birkenmeier EH, et al. (1998) Differential susceptibility of inbred mouse strains to dextran sulfate sodium-induced colitis. The American journal of physiology 274: G544-551.
25. Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y, et al. (1990) A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 98: 694-702. (Pubitemid 20069706)
26. Cooper HS, Murthy SN, Shah RS, Sedergran DJ (1993) Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Laboratory investigation; a journal of technical methods and pathology 69: 238-249.
27. Tsuboi K, Shimura T, Masuda N, Ide M, Tsutsumi S, et al. (2007) Galectin-3 expression in colorectal cancer: relation to invasion and metastasis. Anticancer research 27: 2289-2296.
28. Lotz MM, Andrews CW, Jr., Korzelius CA, Lee EC, Steele GD, Jr., et al. (1993) Decreased expression of Mac-2 (carbohydrate binding protein 35) and loss of its nuclear localization are associated with the neoplastic progression of colon carcinoma. Proceedings of the National Academy of Sciences of the United States of America 90: 3466-3470. (Pubitemid 23111387)
29. Arfaoui-Toumi A, Kria-Ben Mahmoud L, Ben Hmida M, Khalfallah MT, Regaya-Mzabi S, et al. (2010) Implication of the Galectin-3 in colorectal cancer development (about 325 Tunisian patients). Bulletin du cancer 97: E1-8.
30. Schoeppner HL, Raz A, Ho SB, Bresalier RS (1995) Expression of an endogenous galactose-binding lectin correlates with neoplastic progression in the colon. Cancer 75: 2818-2826.
31. Endo K, Kohnoe S, Tsujita E, Watanabe A, Nakashima H, et al. (2005) Galectin-3 expression is a potent prognostic marker in colorectal cancer. Anticancer research 25: 3117-3121.
32. Radosavljevic G, Volarevic V, Jovanovic I, Milovanovic M, Pejnovic N, et al. (2012) The roles of Galectin-3 in autoimmunity and tumor progression. Immunologic research 52: 100-110.
33. Hale LP, Cianciolo G (2008) Treatment of experimental colitis in mice with LMP-420, an inhibitor of TNF transcription. Journal of inflammation 5: 4.
34. Loddenkemper C, Keller S, Hanski ML, Cao M, Jahreis G, et al. (2006) Prevention of colitis-associated carcinogenesis in a mouse model by diet supplementation with ursodeoxycholic acid. International journal of cancer Journal international du cancer 118: 2750-2757.
35. De Robertis M, Massi E, Poeta ML, Carotti S, Morini S, et al. (2011) The AOM/DSS murine model for the study of colon carcinogenesis: From pathways to diagnosis and therapy studies. Journal of carcinogenesis 10: 9.
36. Clapper ML, Cooper HS, Chang WC (2007) Dextran sulfate sodium-induced colitis-associated neoplasia: a promising model for the development of chemopreventive interventions. Acta pharmacologica Sinica 28: 1450-1459. (Pubitemid 47366692)
37. Tanaka T, Kohno H, Suzuki R, Yamada Y, Sugie S, et al. (2003) A novel inflammation-related mouse colon carcinogenesis model induced by azoxymethane and dextran sodium sulfate. Cancer science 94: 965-973. (Pubitemid 37508979)
38. Suzuki R, Kohno H, Sugie S, Tanaka T (2005) Dose-dependent promoting effect of dextran sodium sulfate on mouse colon carcinogenesis initiated with azoxymethane. Histology and histopathology 20: 483-492. (Pubitemid 40468268)
39. Ni J, Chen SF, Hollander D (1996) Effects of dextran sulphate sodium on intestinal epithelial cells and intestinal lymphocytes. Gut 39: 234-241. (Pubitemid 26276001)
40. Dieleman LA, Palmen MJ, Akol H, Bloemena E, Pena AS, et al. (1998) Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines. Clinical and experimental immunology 114: 385-391. (Pubitemid 28539597)
41. Owen CR, Yuan L, Basson MD (2008) Smad3 knockout mice exhibit impaired intestinal mucosal healing. Laboratory investigation; a journal of technical methods and pathology 88: 1101-1109.
42. Ashcroft GS, Yang X, Glick AB, Weinstein M, Letterio JL, et al. (1999) Mice lacking Smad3 show accelerated wound healing and an impaired local inflammatory response. Nature cell biology 1: 260-266. (Pubitemid 129495775)
43. Arany PR, Flanders KC, Kobayashi T, Kuo CK, Stuelten C, et al. (2006) Smad3 deficiency alters key structural elements of the extracellular matrix and mechanotransduction of wound closure. Proceedings of the National Academy of Sciences of the United States of America 103: 9250-9255. (Pubitemid 43902564)
44. Tokumasa A, Katsuno T, Tanaga TS, Yokote K, Saito Y, et al. (2004) Reduction of Smad3 accelerates re-epithelialization in a murine model of colitis. Biochemical and biophysical research communications 317: 377-383. (Pubitemid 38452493)
45. Latella G, Vetuschi A, Sferra R, Zanninelli G, D'Angelo A, et al. (2009) Smad3 loss confers resistance to the development of trinitrobenzene sulfonic acid-induced colorectal fibrosis. European journal of clinical investigation 39: 145-156.
46. Erdman SE, Rao VP, Poutahidis T, Ihrig MM, Ge Z, et al. (2003) CD4(+)CD25(+) regulatory lymphocytes require interleukin 10 to interrupt colon carcinogenesis in mice. Cancer research 63: 6042-6050. (Pubitemid 37187508)
47. Boulard O, Kirchberger S, Royston DJ, Maloy KJ, Powrie FM (2012) Identification of a genetic locus controlling bacteria-driven colitis and associated cancer through effects on innate inflammation. The Journal of experimental medicine 209: 1309-1324.
48. Erdman SE, Poutahidis T, Tomczak M, Rogers AB, Cormier K, et al. (2003) CD4+ CD25+ regulatory T lymphocytes inhibit microbially induced colon cancer in Rag2-deficient mice. The American journal of pathology 162: 691-702. (Pubitemid 36267876)
49. Becker C, Fantini MC, Neurath MF (2006) TGF-beta as a T cell regulator in colitis and colon cancer. Cytokine & growth factor reviews 17: 97-106. (Pubitemid 43117519)
50. Thaker AI, Rao MS, Bishnupuri KS, Kerr TA, Foster L, et al. (2013) IDO1 Metabolites Activate beta-catenin Signaling to Promote Cancer Cell Proliferation and Colon Tumorigenesis in Mice. Gastroenterology 145: 416-425 e414.
51. Hamilton SR, Aaltonen LA (2000) Pathology and Genetics of Tumours of the Digestive System. World Health Organization Classification of Tumours Lyon: International Agency for Research on Cancer (IARC) Press.. 105-119.
52. Percy DH, Barthold SW (2007) Pathology of Laboratory Rodents and Rabbits, Third Edition. Ames, Iowa: Blackwell Publishing. page 61 p.
53. Molavi D, Argani P (2008) Distinguishing benign dissecting mucin (stromal mucin pools) from invasive mucinous carcinoma. Advances in anatomic pathology 15: 1-17. (Pubitemid 351627649)
54. Ronnett BM (2003) Pseudomyxoma peritonei:pathologic features, site of origin and prognosis. CME Journal of Gynecologic Oncology 8: 192-198.
55. Ronnett BM, Yan H, Kurman RJ, Shmookler BM, Wu L, et al. (2001) Patients with pseudomyxoma peritonei associated with disseminated peritoneal adenomucinosis have a significantly more favorable prognosis than patients with peritoneal mucinous carcinomatosis. Cancer 92: 85-91. (Pubitemid 32623044)